Teva (TEVA) Hits All-Time High as Q3 Strengthens FY25 Profitability Expectations

We recently published 10 Big Names Leading Wall Street Gains. Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is one of the best-performing stocks on Wednesday.

Teva rallied to a new all-time high on Wednesday after a stellar performance in the third quarter solidified expectations for a profitable full-year 2025.

In intra-day trading, Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) jumped to a new record high of $25 before trimming gains to finish the day just up by 20.23 percent at $24.60 apiece.

This followed the company’s net income of $460 million in the third quarter of the year, marking a 211 percent improvement from the $390 million net loss in the same period last year.

Revenues grew by 3.4 percent to $4.48 billion from $4.33 billion year-on-year, on the back of strong growth across its brands Austedo, Ajovy, and Uzedy, with sales jumping by 38 percent, 19 percent, and 24 percent, respectively.

Despite the results, Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) reduced the upper range of its revenue growth outlook to $17 billion from $17.2 billion previously, while the lower end was maintained at $16.8 billion.

For adjusted EBITDA, Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) expects figures to end between $4.8 billion to $5 billion, higher than the previous lower end of $4.7 billion.

While we acknowledge the potential of TEVA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.